All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
EMA approval of lenalidomide plus rituximab for adult patients with R/R FL
Bookmark this article
The Lymphoma Hub has recently covered news on the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use, issuing a positive opinion for the approval of lenalidomide plus rituximab (R2) as a treatment for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). You can read it here.
On the 20th of December 2019, the R2 combination was approved by the EMA, based on the positive data from multi-center phase III studies AUGMENT (NCT01938001) and MAGNIFY (NCT01996865).1
You can read the Lymphoma Hub’s coverage of the AUGMENT study, watch an interview with Marek Trněný discussing the post-hoc analysis of the data in the elderly population, and Mathias Rummel discussing the MAGNIFY trial.
- Bristol-Myers Squibb. Bristol-Myers Squibb receives European Commission approval for Revlimid® (lenalidomide) in combination with rituximab for the treatment of adult patients with previously treated follicular lymphoma. December 20, 2019. https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-receives-european-commission-approval-rev. Published; December 20, 2019, [Accessed January 3 2020]
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox